XML 41 R29.htm IDEA: XBRL DOCUMENT

Segment, Geographical and Other Revenue Information (Tables)

3 Months Ended

Mar. 31, 2021

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated income (loss) before income taxes (in thousands):


	Three months ended March 31, 2021						Three months ended March 31, 2020
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	10,226	$	—	$	10,226	$	5,100	$	—	$	5,100
Research and development revenue	4,003		3,803		7,806		5,774		3,796		9,570
Total revenues	14,229		3,803		18,032		10,874		3,796		14,670
Costs and operating expenses:
Cost of product revenue	4,218		—		4,218		2,541		—		2,541
Research and development(1)	6,444		4,605		11,049		5,696		4,925		10,621
Selling, general and administrative(1)	2,818		600		3,418		2,345		591		2,936
Total segment costs and operating expenses	13,480		5,205		18,685		10,582		5,516		16,098
Income (loss) from operations	$	749	$	(1,402)	(653)		$	292	$	(1,720)	(1,428)
Corporate costs (2)					(7,728)						(5,727)
Unallocated depreciation and amortization					(685)						(492)
Loss before income taxes					$	(9,066)					$	(7,647)

(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.

(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following table provides stock-based compensation expense included in income (loss) from operations (in thousands):


	Three months ended March 31,
	2021								2020
	Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total		Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total
Stock-based compensation	$	994	$	238	$	1,455	$	2,687	$	756	$	241	$	1,172	$	2,169

Schedule of customers that contributed 10% or more of total accounts receivable

Significant Customers

Customers that each accounted for 10% or more of our total revenues were as follows:


	Percentage of Total Revenues for the
	Three Months Ended March 31,
	2021		2020
Customer A	28	%	24	%
Customer B	*		19	%
Customer C	11	%	15	%
Customer D	10	%	11	%
Customer E	14	%	*
* Percentage was less than 10%

Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:


	Percentage of Accounts Receivables as of
	March 31, 2021		December 31, 2020
Customer A	41	%	32	%
Customer B	*		25	%
Customer D	11	%	13	%
Customer F	12	%	*
Customer G	11	%	*
* Percentage was less than 10%

Schedule of revenues by geographical area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):


	Three Months Ended March 31,
	2021		2020
Revenues
Americas	$	4,929	$	5,225
EMEA	6,282		5,971
APAC	6,821		3,474
Total revenues	$	18,032	$	14,670

Schedule of long-lived assets by geographical area

Identifiable long-lived assets by location was as follows (in thousands):


	March 31, 2021		December 31, 2020
United States	$	31,248	$	31,176

Schedule of intangible assets and goodwill

Identifiable goodwill by reporting unit was as follows (in thousands):


	As of March 31, 2021 and December 31, 2020
	Performance Enzymes		Novel Biotherapeutics		Total
Goodwill	$	2,463	$	778	$	3,241